Abstract: Herein described are variants of parathyroid hormone that retain significant PTH activity and are substantially resistant to trypsin and trypsin-like enzymes. The variants are useful pharmaceutically, to treat bone disorders such as osteoporosis and in other therapeutic applications. Specific embodiments of the invention include [His.sup.25 ]PTH and [His.sup.25 His.sup.26 Leu.sup.27 ]PTH.
Type:
Grant
Filed:
April 3, 1992
Date of Patent:
January 17, 1995
Assignees:
Allelix Biopharmaceuticals Inc., Glaxo Canada Inc.
Abstract: Inflammation in mammals is treated by administering anti-inflammatory agent complexed with corticosteroid binding globulin (CBG) that is produced by recombinant DNA-based techniques.
Abstract: Essentially pure human interleukin-6 having a purity of at least 98 % as determined by single peak migration using capillary electrophoresis is obtained by a 3-step purification method which includes a cation-exchange chromatography step, a hydrophobic chromatography step and a reverse-phase chromatography step in the presence of a charge modifier.
Abstract: Herein described is an ovarian cancer activating factor that has been isolated from ovarian cancer ascites fluid. The factor may be utilized in its isolated form in a screening program aimed at identifying inhibitors of factor-mediated ovarian cancer activation, or as a growth supplement useful for culturing ovarian and other cancer cell lines.
Abstract: Human epidermal growth factor is provided in an ultrapure form characterized by the absence of protein contaminants detectable by capillary electrophoresis analysis. A method for obtaining such ultrapure human epidermal growth factor includes fractionation of a human epidermal growth factor preparation by reversed phase high performance liquid chromatography in the presence of a cationic ion-pairing agent.
Abstract: Herein described is an ovarian cancer activating factor that has been isolated from ovarian cancer ascites fluid. The factor may be utilized in its isolated form in a screening program aimed at identifying inhibitors of factor-mediated ovarian cancer activation, or as a growth supplement useful for culturing ovarian and other cancer cell lines.
Abstract: Biologically active variants of epidermal growth factor are provided, comprising tandemly linked units of monomeric EGF. The variants are useful per se as therapeutic agents to promote wound healing. Production of the multimeric EGF by genetically engineered microbial hosts is also described.
Type:
Grant
Filed:
March 1, 1989
Date of Patent:
June 8, 1993
Assignee:
Allelix Biopharmaceuticals, Inc.
Inventors:
Zimin Guo, A. Michael Sills, Nigel A. Skipper
Abstract: Human parathyroid hormone is provided in an ultrapure form characterized by the absence of protein contaminants detectable by capillary electrophoresis analysis. A method for obtaining such ultrapure human parathyroid hormone is also described.
Type:
Grant
Filed:
May 23, 1991
Date of Patent:
May 4, 1993
Assignees:
Allelix Biopharmaceuticals Inc., Glaxo Canada Inc.
Abstract: The invention relates to constitutive promoters useful to control gene expression in Aspergillus hosts. The promoters are derived from the Aspergillus nidulans aldA gene.
Abstract: Described is a purified osteogenic factor that when delivered to bone in association with a physiologically acceptable delivery vehicle is capable of inducing new bone growth at the bone surface. The osteogenic factor is water soluble, and is characterized physically by a molecular weight of about 2.5 kD when measured by gel filtration under dissociating conditions and an isoelectric point in the pH range from about 4.6 to 7.2. Use of the purified factor in treating bone defects is described. Also described is a method for obtaining the purified factor from mammalian bone.
Type:
Grant
Filed:
March 28, 1991
Date of Patent:
December 8, 1992
Assignees:
Allelix Biopharmaceuticals Inc., Glaxo Canada Inc.
Inventors:
Alain E. Lagarde, Abdulwahid Abdulwajid, Donna Bueschkens, Deanna Byrne
Abstract: Interferon .beta..sub.2 has been identified as the major factor responsible for stimulating hepatocytes to produce anti-inflammatory agents. A method for its use in so stimulating hepatocytes is described herein.
Type:
Grant
Filed:
July 20, 1987
Date of Patent:
November 27, 1990
Assignee:
Allelix Biopharmaceuticals, Inc.
Inventors:
Jack Gauldie, Richards, Carl, Peter M. Lansdorp
Abstract: 3',4'-anhydrovinblastine, a precursor of the anti-tumor alkaloids vincristine and vinblastine, is prepared by the enzymatic coupling of catharanthine and vindoline using an iron-containing compound such as peroxidase optionally in the presence of a peroxide. Substantially enhanced yields are obtained.
Type:
Grant
Filed:
August 4, 1986
Date of Patent:
April 17, 1990
Assignee:
Allelix Biopharmaceuticals Inc.
Inventors:
Anne E. Goodbody, Endo Tsuyoshi, John Vukovic, Masanaru Misawa